VYGR — Voyager Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$3.93
Market Cap$234M
Float44.2M
Shares Outstanding60.4M
P/E (Forward)8.44
Price/Sales (TTM)6.42
vs. Analyst Target+278.9% to analyst PT
Operating Margin (TTM)-1167.37%
Revenue (TTM)$36.5M
Dividend RateNone
Analyst Target Price$14.89 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $171M $36.7M $62.4M $31.2M
2021 $37.4M -$66.0M $37.4M -$68.5M
2022 $40.9M -$46.4M $40.9M -$44.6M
2023 $250M $132M $158M $126M
2024 $80.0M -$65.0M $80.0M -$78.6M
2025 $40.4M -$120M $40.4M -$128M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $5.2M -$33.4M
Sep 2025 $13.4M -$27.9M
Dec 2025 $15.3M -$27.4M
Mar 2026 $2.6M -$27.9M

Ownership & Float

Insider Ownership15.1%
Institutional Ownership56.4%
Short Float8.3%
% of All Funds Holding1.46%
Number of Funds Holding120

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$3.89Near-term / short-term trend
Weekly40-Week SMA$4.08Medium-term trend
Weekly80-Week SMA$4.12Cyclical trend (business cycle)
Weekly200-Week SMA$6.36Secular trend (multi-year)
Monthly10-Month SMA$4.02Near-term monthly trend
Monthly20-Month SMA$4.26Medium-term monthly trend
Monthly40-Month SMA$6.25Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$3.40 support 1.53x 7 months ago
$9.50 resistance 1.17x 24 months ago

Historical Earnings Reactions (43 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.86% -0.10% 39.53% 7.34% -19.94%
1 Day -0.57% 0.18% 51.16% 21.65% -23.21%
1 Week -2.28% -0.97% 44.19% 40.08% -28.05%
2 Weeks -1.97% -3.08% 34.88% 73.09% -38.17%
1 Month -0.53% 0.15% 50.00% 69.13% -40.21%

Next earnings: July 26, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan0.4%45.5%11
Feb5.8%54.5%11
Mar3.8%45.5%11
Apr1.4%45.5%11
May4.1%60.0%10
Jun1.0%50.0%10
Jul-1.9%40.0%10
Aug-2.1%60.0%10
Sep7.1%20.0%10
Oct-1.0%30.0%10
Nov-7.9%40.0%10
Dec-3.6%45.5%11

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.10% 50.2% 494
Tuesday 0.17% 49.8% 546
Wednesday 0.38% 49.8% 542
Thursday -0.41% 46.7% 533
Friday 0.04% 47.7% 532

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 56.4%

Insider Transactions — Smart Summary

Total insider ownership: 15.1%

12-Month Insider Activity Summary

Total Filings13
Net Value-$405,470.24
Net Shares Change-106,875
% of Float-0.2%
C-Suite Filings13
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Sandrock Alfred President and CEO -$138,360.32 3 N/A
Ferguson Toby Chief Medical Officer -$70,870 1 1 sell
Jorgensen Nathan D. Chief Financial Officer -$54,241.84 2 N/A
Swartz Robin COO and CBO -$41,937.31 2 N/A
Carter Todd Alfred Chief Scientific Officer -$27,049.68 2 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-02-11 – 2026-02-20 6 3 -$141,963.3 6 C-suite
2026-02-26 – 2026-02-26 4 4 -$111,445.89 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-08-20 Ferguson Toby Chief Medical Officer -$70,870 Transaction at $3.73, now +5.4%
2026-04-03 Sandrock Alfred President and CEO -$44,547.57 Transaction at $3.87, now +1.6%
2026-02-26 Swartz Robin COO and CBO -$24,346.66 Transaction at $3.77, now +4.2%
2026-02-26 Sandrock Alfred President and CEO -$53,806.63 Transaction at $3.79, now +3.7%
2026-02-26 Jorgensen Nathan D. Chief Financial Officer -$17,598.36 Transaction at $3.77, now +4.2%
2026-02-26 Carter Todd Alfred Chief Scientific Officer -$15,694.24 Transaction at $3.76, now +4.5%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Voyager Therapeutics Inc (VYGR) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for VYGR on Trend Edge →